-
Press Release
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
-
Press Release
NEJM publication of Novartis Kisqali® data shows longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Press Release
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
-
Press Release
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
-
Press Release
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
-
Press Release
Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
-
Press Release
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
-
Press Release
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
-
Press Release
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
-
Press Release
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
-
Story
When it comes to cancer, there’s power in a good partner -
Story
Solving the puzzle of immunotherapy